- Pyxis Oncology (NASDAQ:PYXS) said it has completed the sale of its rights to royalties from the commercialization of Beovu and another asset to Novartis for a one-time cash payment of $8 million.
- The company will record the $8 million payment in Q1 2024, and will retain rights to three other antibodies in development by Apexigen's licensees.
Pyxis Oncology gets $8M payment for sale of royalty rights
Recommended For You
More Trending News
About PYXS Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| PYXS | - | - |
| Pyxis Oncology, Inc. | ||